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Abstract
Background: Individually tailored cancer treatment is essential to ensure optimal treatment and resource use.
Treatments for incurable metastatic non-small cell lung cancer (NSCLC) are evolving rapidly, and decision support
systems (DSS) for this patient population have been developed to balance benefits and harms for decision-making.
The aim of this systematic review was to inventory DSS for stage IIIB/IV NSCLC patients.
Methods: A systematic literature search was performed in Pubmed, Embase and the Cochrane Library. DSS were
described extensively, including their predictors, model performances (i.e., discriminative ability and calibration),
levels of validation and user friendliness.
Results: The systematic search yielded 3531 articles. In total, 67 articles were included after additional reference
tracking. The 39 identified DSS aim to predict overall survival and/or progression-free survival, but give no
information about toxicity or cost-effectiveness. Various predictors were incorporated, such as performance status,
serum and inflammatory markers, and patient and tumor characteristics. Some DSS were developed for the entire
incurable NSCLC population, whereas others were specifically for patients with brain or spinal metastases. Few DSS
had been validated externally using recent clinical data, and the discrimination and calibration were often poor.
Conclusions: Many DSS have been developed for incurable NSCLC patients, but DSS are still lacking that are up-to-
date with a good model performance, while covering the entire treatment spectrum. Future DSS should
incorporate genetic and biological markers based on state-of-the-art evidence, and compare multiple treatment
options to estimate survival, toxicity and cost-effectiveness.
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Background
According to the World Health Organization, cancer is
one of the leading causes of morbidity and mortality
worldwide, with lung cancer in the top five of cancers
and the leading cause of cancer mortality with 1,6 mil-
lion deaths in 2012 [1]. Roughly 80–85% of lung cancers
are non-small cell lung cancer (NSCLC) [2]. Staging in
patients is based on the Tumor Node Metastasis (TNM)
classification, which is shown to be an important pre-
dictor of survival [3, 4]. Incurable patients with initial or
recurrent metastatic NSCLC (stages IIIB and IV) have a
short life expectancy, with 1-, 2- and 3-years survival
ranging between 22 and 47%, 8–26% and 4–17%, re-
spectively [5].
The current treatment of incurable NSCLC patients
consists of systemic chemotherapy (CT), radiotherapy
(RT), therapies targeting oncodrivers (e.g., epidermal
growth factor receptor tyrosine kinase inhibitors, EGFR-
TKI) or the immune system (immunotherapies), in
addition to best supportive care (e.g., pain relief ). In spe-
cific patient groups, mainly palliative surgery (for spinal
metastases) and RT (for brain metastases) are advised.
Palliative treatments aim to preserve or improve quality
of life, lengthen life or decrease disease burden.
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Palliation can target the tumor tissue itself or symptoms,
such as pain, diarrhea, obstipation, anxiety or depres-
sion. Individually tailored palliative cancer treatment is
essential to ensure that patients receive the treatment
that optimally matches their values and preferences,
avoiding under- or overtreatment, and optimally utilizing
available healthcare resources. However, this is a chal-
lenge due to the heterogeneity of the patient population,
the multiple treatment options, and the marginal ex-
pected treatment benefits. Therefore, decision making in
the palliative phase can be complex, as there is a delicate
balance between benefits (e.g., symptom relief, life
lengthening) and harms of treatments (e.g., side effects,
loss of quality of life), as well as the costs of treatment.
Decision support systems (DSS) could assist physicians
in formulating an evidence-based treatment advice. DSS
(e.g., prediction models, nomograms or decision trees)
are based on statistical models in order to predict out-
comes, such as overall survival (OS) (with our without
treatment), toxicity and cost-effectiveness. They are
based on patient and tumor characteristics, and prefera-
bly compare various treatment options. Research has
shown that such clinical prediction models in end-of-life
care are valued by physicians, because they enhance
prognostic confidence and improve communication with
patients, although they can also cause emotional distress
in patients and raise prognostic overconfidence despite
uncertainty in palliative care [6].
In patients with incurable NSCLC, some overviews have
been published that summarize DSS in NSCLC patients.
For instance, Mahar et al. have performed a systematic lit-
erature search from 1996 until 2015, identifying a total of
32 tools for all stages of lung cancer [7]. They described
that the majority of the prediction models focus on NSCLC
patients with metastatic disease, which can be explained by
a larger need for DSS in this specific clinical population [7].
However, they did not use an extensive literature search
with a large variety of MeSH headings, and thus, might
have missed DSS for this subgroup. Other reviews have de-
scribed DSS specifically developed either for patients with
spinal metastases [8] or brain metastases, largely consisting
of incurable NSCLC patients [9–12]. However, none of the
earlier studies focused on the available DSS for the entire
incurable NSCLC population, having short survival times
due to rapidly progressive disease, whilst on the other hand
there are rapid developments of new treatment options.
Tools that aid clinical decision-making in this complex
subgroup are urgently needed to help oncologists navigate
the ever-growing maze of treatment options.
We conducted an extensive systematic literature
search in order to summarize the available DSS for in-
curable patients with (initial or recurrent) metastatic
NSCLC (stages IIIB and IV). We will give an overview of
the development studies and the included predictors, as
well as the levels of validation and calibration, and the
model performances. Furthermore, we add concluding
remarks about the user friendliness and ease of access of
the identified DSS in clinical practice, and give direction
to future research in this rapidly evolving field.
Methods
Literature search
A systematic literature search was performed in
Pubmed, Embase and the Cochrane Library (until Febru-
ary 2016), in collaboration with the VU University Med-
ical Center Medical Library. Titles and abstracts were
retrieved and screened by three independent reviewers
(DR, VC and JT), and discrepancies were resolved
through consensus. After identification of potentially
relevant papers, one researcher (DR) made the final se-
lection of DSS by screening the full text papers, and
when in doubt about inclusions VC, HdV, JT and FS
were consulted. The search strategy consisted of a com-
bination of database-specific MeSH terms, free text, ‘wild
cards’ (words truncated by using “*”) and Boolean opera-
tors (“AND”, “OR”, “NOT”) (Additional file 1: Table S1).
Inclusion and exclusion criteria are shown in Table 1. We
followed the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) Statement [13],
which are listed in the Supplemental PRISMA checklist.
After selecting DSS from the systematic literature
search, a manual search was performed to find the rele-
vant development and validation studies for each DSS.
First, references of the included papers were checked.
Then, a ‘Cited by’ function and manual search were
Table 1 Inclusion and exclusion criteria for literature search
Inclusion criteria for papers:
- Describing development, validation or updating of a DSS;
- Describing DSS that aims to predict prognosis (overall survival or
progression-free survival), optimal treatment selection or toxicity;
- Describing DSS that is depicted either as a risk score with a formula,
nomogram, decision tree or (online) calculator or application.
- Describing DSS that is applied in incurable patients with (initial or
recurrent) metastatic NSCLC (stages IIIB and IV).
- Describing DSS that is developed or validated in clinical data
collected after 2000, as older data would not correctly reflect the
current clinical practices anymore;
- Papers published in English.
Exclusion criteria for papers:
- Examining early stage NSCLC patients or patients with
oligometastases;
- Comparing treatments with curative intention or predicting whether
curing metastases is still possible;
- Describing univariate or multivariate analyses where only Hazard
ratios or Odds ratios are reported, but no calculation of survival time for
individual patients;
- Non-original papers (e.g., reviews, methodological papers) only used
for reference tracking;
- Describing separate parameters that cannot be applied as an
independent DSS;
- Describing general tools that are not developed or validated in stage
IIIB/IV NSCLC.
Révész et al. BMC Medical Informatics and Decision Making  (2017) 17:144 Page 2 of 12
performed in Pubmed, using the following terms: “name
DSS” AND “lung” AND “validate”. We also searched for
additional DSS on a DSS indexing website (http://
www.MedicalAlgorithms.com), and scanned the websites
of the National Comprehensive Cancer Network (NCCN),
European Society for Medical Oncology (ESMO), Ameri-
can Society of Clinical Oncology (ASCO), National Insti-
tute for Health and Care Excellence [14] and International
Association for the Study of Lung Cancer (IASLC).
When many validation studies were found for a DSS,
studies were selected when their sample size was >150
and/or they reported an impact analysis (i.e., prospect-
ively treating patients according to a DSS, and evaluating
the outcome).
Data extraction
The quality of the included DSS was assessed by one re-
searcher (DR) using an abbreviated CHARMS checklist
[15], as shown in Table 2, and VC, HdV and JT were
consulted for consensus when necessary. Model per-
formance was assessed with measures for the discrim-
inative ability of DSS (i.e., C-indices, area under the
curve measures (AUC)), the Van Calster levels of calibra-
tion [16] and the Reilly levels of evidence [17]. Conclu-
sions about user friendliness were drawn based on
whether the predictors were routinely collected, whether
individual scores could be easily calculated and whether
additional online or paper tools are available.
Results
Overview retrieved articles
With the systematic literature search a total of 3.531 ar-
ticles were retrieved, of which 39 DSS were identified
(Fig. 1). The included DSS were developed using data
from a wide range of settings/contexts (i.e., clinical trials,
prospective, and retrospective cohorts) and countries
across most continents. Whereas some DSS can be used
in all NSCLC patients (N = 21), others were specifically
for patients with brain (N = 14), bone (N = 1) or spinal
metastases (N = 3). Overall, these DSS aimed to predict
prognosis (i.e., overall survival (OS) or progression-free
survival (PFS)) in patients before or during treatments,
such as systemic therapy (N = 6), RT, surgery and/or
symptom management for brain metastases (N = 14) or
for spinal metastases (N = 3), targeted therapies (N = 6),
the general choice between tumor targeting vs. symptom
management (N = 6), or mixed treatments (N = 4). No
DSS were identified that predict the risk of side-effects
or cost-effectiveness of treatments.
Additional file 2: Table S2 gives an overview of the 39
included DSS for incurable NSCLC patients, alongside
their development and validation studies, predictors and
outcomes, model performances and user friendliness.
The 39 DSS included a multitude of predictors, of which
performance status, age, extracranial metastases and
serum albumin levels were the most frequently incorpo-
rated in DSS, whereas EGFR status was the only genetic
marker. Figure 2 shows the predictors that have been in-
corporated in at least two DSS. Next, Fig. 3 shows an
overview of the variations in discriminatory ability (area
under the ROC curve, AUC), the levels of validation and
calibration in the retrieved DSS, and their user friendli-
ness (i.e., routine collection and ease of access). The DSS
that have been validated externally are discussed below
and grouped based on the treatment options that they
are developed for or validated in.
DSS for general tumor targeting treatment vs. symptom
management
A group of prognostic scores is based on the systemic
inflammatory response, as chronic activation of this
response typically goes along with negative outcomes
(e.g., worse survival) [19]. Forrest et al. developed the
Glasgow Prognostic Score (GPS, Table 3) that divides
patients into three risk categories, with a higher score
corresponding to shorter survival times [19]. Thereby,
the GPS aids in deciding when it is worthwhile to pro-
vide intensive tumor-targeting treatment or merely
symptom-management, although it is not clearly stated
Table 2 Quality assessment checklist for included DSS
Model performance
Discriminative ability
Measuring how well DSS distinguishes between outcomes (e.g., risk
groups) in external validations, using area under the ROC curve (AUC)
analyses. AUC: <0.6 = poor; 0.6–0.7 = moderate; 0.7–0.8 = strong;
>0.8 = very strong [18]
van Calster levels of calibration (16)
Measuring how well predicted outcomes resemble observed outcomes:
- Mean calibration – Correct average predicted risk.
- Weak calibration – Correct average prediction effects.
- Moderate calibration – Comparison between predicted and observed
outcome.
- Strong calibration – Event rate equals predicted risk for every covariate
pattern.
Reilly levels of evidence (17)
Measure for how thoroughly DSS is validated:
- Level 1 – Derivation from a prediction model and not externally
validated yet.
- Level 2 – Narrow validation in one setting.
- Level 3 – Broad validation in varied settings and populations.
- Level 4 – Narrow impact analysis of model as decision rule in one
setting.
- Level 5 – Broad impact analysis of model as decision rule in varied
settings and populations.
User friendliness
Predictors routinely collected
Are all predictors in the DSS collected on a routine basis in clinical
practice, or are special techniques needed?
Easy use and access
Can the DSS easily be calculated (manually or using a computer) with
an accessible regression formula, scoring system, nomogram, decision
tree or online application?
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which risk category should not be treated intensively
anymore [19]. Subsequently, various GPS-related models
have been developed to measure the impact of inflam-
matory status on survival (scores are summarized in
Table 3). The most frequently validated scores are the
GPS, modified Glasgow Prognostic Score (mGPS) [20],
and the Prognostic Index (PI) [21], but other scores that
have not been validated externally were the advanced
lung cancer inflammation index (ALI) [22], the Montreal
Prognostic score [23, 24] and the Laboratory prognostic
index (LPI) [25]. The GPS has an online calculator,
which makes it easier to use in clinical practice [26]. Al-
though the GPS predicts survival more accurately than
the mGPS (higher AUC) [27], and its calibration is
found to be better than the PI, its discriminative ability
is found to be moderate with an AUC-value between
0.6–0.7 [28].
DSS for systemic therapy
A few prognostic scores have been developed to select
patients in which first line systemic therapy should be
considered, such as the Hoang nomogram [29] and the
Sanchez-Lara score [30], but these models have not been
validated externally. Then, if patients manifest with dis-
ease progression after first line treatment, they might be
suitable for second (or third) line treatment. For the lat-
ter group of patients, the Di Maio score was developed
[23]. It takes various demographic and clinical factors
into account, and divides patients into three prognostic
groups (i.e., good, moderate and poor prognosis). How-
ever, the authors did not formulate any cut-offs for
which groups should be considered for treatment. A
2012 validation study reported high discrimination
(AUC = 0.926) for the Di Maio score [31]. However, the
score is developed and validated with 10 year old clinical
Fig. 1 Flowchart of systematic literature search and article selection
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data, has not been validated in other settings, and there
are no user friendly applications available.
DSS for targeted therapy
The Florescu prognostic score was developed based on
data from a clinical trial comparing erlotinib vs. placebo
as a second or third line treatment [32]. Its estimates are
based on patient, lifestyle, tumor, and treatment charac-
teristics, and EGFR status. A total score can easily be cal-
culated from the table in the paper, and it divides patients
into four risk groups. The Florescu score was modified
later in a small Polish sample [33], but only the original
scoring system is validated in another patient group that
received gefitinib, and none of these studies reported any
measures of calibration or discrimination [34]. Moreover,
the clinical data used in these studies was old (develop-
ment study: 2001–2003 vs. validation study: 2003–2004),
and no online applications are available. Nowadays, EGFR
status would not be included into a model for EGFR-TKI
treatment, as none of the patients without the mutation
would be treated with EGFR-TKIs.
DSS for RT, surgery and/or symptom management in
patients with brain metastases
Other prognostic scores aim to predict prognosis in patients
with brain metastases resulting from various primary tumor
types, but the development and validation populations often
included large numbers of NSCLC patients. The population
with brain metastases is heterogeneous, and oncologists
have to weigh harms and benefits for each individual patient
in order to choose more intensive treatment or to stick to
conservative symptom palliation. Various DSS have been
developed to predict survival in incurable NSCLC patients
with brain metastases who were undergoing whole brain
Fig. 2 Frequency of predictors in DSS that were used at least two times classified in categories: sociodemographics and lifestyle, physical factors,
tumor characteristics, treatment characteristics, serum and genetic markers. It must be noted that some predictors only apply to subgroups of
patients with specific metastases or treatments
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radiotherapy (WBRT), stereotactic radiosurgery (SRS) or
fractionated stereotactic radiotherapy (SRT) [10, 11, 35,
36], and are summarized in Table 4. First, the Recursive
Partitioning Analyses (RPA) score was developed [37].
Later, the RPA score was modified twice into the modified
RPA I and II [38, 39], and other DSS were derived, such as
the Rotterdam score (RDAM) [40], Score Index for Radio-
surgery (SIR) [41], Basic Score for Brain Metastases
(BSBM) [42], modified BSBM score that included infor-
mation regarding neurological complications and survival
[43], Graded Prognostic Assessment (GPA) [44], Rades I
[45] and Rades II score [46].
After Golden et al. reported that primary tumor type is a
significant predictor as well [47], they developed the Golden
Grading System (GGS) in subsamples of patients with vari-
ous primary tumors, including NSCLC [47]. Subsequently,
various studies have been published with diagnosis-specific
prognostic scores. The GPA has been tested in various pop-
ulations (NSCLC, breast cancer and gastro-intestinal can-
cer), in order to create the disease-specific GPA (ds-GPA)
[48], and Rades et al. developed the NSCLC-specific Rades
score (NSCLC-Rades) [49]. A well-calibrated nomogram
was created by Barnholtz-Sloan et al., incorporating primary
tumor type into the model [50].
Some of the RPA-related scores have been validated re-
peatedly and tested for their discriminative ability in the lit-
erature. The reported AUC’s were moderate and varied
Fig. 3 Frequency of DSS with discriminatory ability (A: area under the curve / C-index), levels of calibration (B), validation (C) and user friendliness
(D: routine collection and ease of access)
Table 3 DSS for choice between tumor targeting treatment vs.
symptom management, based on inflammatory markers
Alb ALP BMI Ca CRP LDH NLR Stage WBC # groups
GPS18 √ √ 3
mGPS19 √ √ 3
PI20 √ √ 3
ALI21 √ √ √ 2
MPS23 √ √ √ √ √ 3
LPI24 √ √ √ √ √ 3
Abbreviations:Alb Albumin, ALI Advanced lung cancer inflammation index, Alp
Alkaline phosphatase, BMI Body mass index, Ca Calcium, CRP C-reactive pro-
tein, GPS Glasgow prognostic score, LDH Lactate dehydrogenase, LPI Labora-
tory prognostic index, mGPS Modified GPS, MPS Montreal prognostic score,
NLR Neutrophil/lymphocyte ratio, PI Prognostic index, WBC White blood cells
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between 0.5–0.7 [10, 11]. However, both the development
papers and validation studies have often used relatively old
clinical datasets (often before 2011), and the clinical rele-
vance is therefore questionable. More recently, Lee et al.
have suggested integrating EGFR mutational status into the
ds-GPA score, which is a valuable step for future DSS [51].
Online tools are available for the RPA [52], GPA [53], and
Barnholtz-Sloan nomogram [54]. Furthermore, the RPA
score is incorporated in the ESMO guidelines and the
Dutch national guidelines for brain metastases [55, 56].
DSS for RT, surgery and/or symptom management in
patients with spinal metastases
For patients with spinal metastases the Tokuhashi score
was revised in 2005, and aims to support the oncologist
when choosing between surgical interventions and a
“more conservative approach” [57]. However, it was not
precisely defined what a “more conservative approach”
entailed [57]. This prognostic model divides patients into
three prognostic groups, and gives an indication for treat-
ment: excisional surgery for the lowest risk group, pallia-
tive surgery for the moderate risk group, and conservative
treatment for the high risk group. The revised Tokuhashi
score was externally validated in NSCLC patients [58, 59],
had a mean level of calibration, but the authors did not re-
port anything about the discrimination. A decision tree is
provided [60], and the score can be found online as a cal-
culator [61]. The revised Tokuhashi is incorporated in the
Dutch national guidelines for spinal metastases [62], al-
though the validation studies reported mixed results. An
impact analysis of this score was performed by Tokuhashi
et al., in which they followed up patients after they had re-
ceived their treatment based on the scores’ prediction
[58]. They found a large overlap of 87.9% between the pre-
dicted prognoses and the observed survival times [58]. On
the other hand, in an external validation of Yu et al., the
predicted and observed survival by the revised Tokuhashi
score overlapped in merely 8.2% of the cases, indicating a
poor predictive accuracy [59].
DSS for mixed treatments
Few DSS have been developed in patient populations
with mixed treatment options, but have not been exter-
nally validated, such as the Daniele score [63], Lin score
[64] and Zhang score [65]. Only the Blanchon model
[66] has been validated in another population [67],
thereby, reaching Reilly level 2. This scoring is developed
to predict risk of death at four years in patients with
various treatments (i.e., CT, surgery, RT, combinations).
However, the calibration of this model has not been re-
ported, and its discriminatory ability was moderate
(AUC = 0.61) in the external validation study [67]. Fur-
thermore, no online tools are available for this DSS.
Discussion
Decision support systems (DSS) aid clinical decision-
making by comparing various treatment options, and by
predicting harms and benefits based on patient and
tumor characteristics. This systematic review provides a
comprehensive overview of DSS developed and/or vali-
dated for incurable patients with (initial or recurrent)
metastatic NSCLC (stages IIIB and IV). In total, 39 DSS
Table 4 DSS for RT, surgery and/or symptom management in patients with brain metastases
Tumor
type
KPS ECM Age Sex Tumor
control
#
lesions
Volume
lesions
Time until
RT
Response
steroids
MD NS #
groups
RPA36 √ √ √ √ 3
RDAM39 √ √ √ 3
SIR40 √ √ √ √ √ 3
mRPA I37 √ √ √ √ 5
BSBM41 √ √ √ 4
GPA43 √ √ √ √ 4
GGS46 √ √ √ 4
Rades I44 √ √ √ √ 4
ds-GPA47 √ √ √ √ 4
Rades II45 √ √ √ √ √ 3
BS
nomogram49
√ √ √ √ √ √ –
mRPA II38 √ √ √ √ 5
NSCLC-Rades48 √ √ √ 3
mBSBM42 √ √ √ √ √ √ √ 8
Abbreviations: BS Barnholtz-Sloan, BSBM Basic score for brain metastases, ds-GPA Disease-specific GPA, ECM Extracranial metastases, GGS Golden Grading System,
GPA Graded prognostic assessment, KPS Karnofsky performance status, mBSBM Modified BSBM, MD Meningeal dissemination, mRPA Modified RPA, NS Neurological
symptoms, NSCLC Non-small cell lung cancer, RDAM Rotterdam score, RPA Recursive partitioning analysis, RT Radiotherapy, SIR Score index for radiosurgery
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have been identified, of which 17 had been externally
validated. Each DSS is described, and an overview is given
of their discrimination, calibration and user friendliness.
These DSS estimate OS and/or PFS, and are based on pa-
tient and treatment characteristics, sociodemographic,
lifestyle and physical factors, serum markers, and to a
lesser extent genetic markers. Regardless of the relatively
large amount of existing DSS, there is room for improve-
ment in the tools for clinical decision-making.
Less than half of the currently available DSS have been
externally validated in a broader setting, and most vali-
dations have also been performed in relatively old data-
sets. Validated tools also showed poor model
performances. Another shortcoming of the currently
available DSS is that they only estimate OS or PFS, but
do not incorporate other outcomes of societal relevance,
such as toxicity or cost-effectiveness. In line with previ-
ous reviews, none of the DSS weigh the risks and bene-
fits of treatments [7, 9–12]. This makes decision-making
difficult, as not all facets are discussed. It should be kept
in mind that DSS only aim to facilitate the decision-
making process. Physician can use information obtained
from DSS to derive a treatment advice, or to inform pa-
tients during consultations. The information obtained
from DSS can help patients develop informed prefer-
ences, which are the basis for shared decision-making. It
is therefore important for DSS to at least provide infor-
mation of both the benefits (in terms of survival) and
harms (in terms of side-effects) of treatment.
Also, most tools are developed to give a rough esti-
mate of survival, either in the entire incurable NSCLC
population, for systemic therapy, targeted therapy, mixed
treatments or specifically for patients with brain or
spinal metastases. There is no DSS that gives an over-
view of all treatments relevant to consider in the incur-
able NSCLC population (or a specific subgroup), or that
offers clear cut-off points for when it is worthwhile to
provide intensive treatment or best supportive care. In
the meantime, studies often lack good definition of the
control conditions, which are described as a ‘more con-
servative approach’ or ‘best supportive care’. Even
though clinical guidelines also describe all available
treatment options, they do not present overviews that
enable individualized decision making. Some currently
identified DSS are incorporated in existing guidelines, al-
though these tools’ performance is mediocre. For in-
stance, the RPA was extensively examined in multiple
studies and is incorporated in the ESMO guidelines [56]
and the Dutch Oncoline guidelines for brain metastases
[55], but its discriminative ability is not at all strong.
The revised Tokuhashi score is only mentioned in the
Dutch national guidelines for spinal metastases [62], al-
though the accuracy of this DSS is not consistently good
in all studies [58, 59]. For more personalized clinical
decision-making, guidelines would ideally incorporate
available DSS based on recent clinical evidence with
good discriminatory ability and calibration that compare
multiple treatment options, and present multiple out-
comes (e.g., benefits, harms and cost-effectiveness).
Within this review, we found that DSS that outper-
formed others (e.g., Di Maio score with AUC = 0.926) or
that have a user friendly lay-out (e.g., Barnholtz-Sloan
nomogram) are not validated in broader settings, and
have not been tested extensively. An explanation for the
lack of optimal tools could be that the current process
of development, validation and updating of DSS is too
time-consuming. Therefore, DSS are expected to be out-
dated by the time that extensive validations can be per-
formed due to the rapid developments in lung cancer
care. Other methods, such as rapid learning techniques
[68, 69] and other sophisticated algorithms might be de-
veloped for more continuous updating and validating
procedures. Another explanation for the relatively poor
model performances might also be that survival in this
heterogeneous group of patients cannot be estimated
with high accuracy. Even though they aim to personalize
decision-making, DSS are based on statistical models
that by definition make use of probabilities. These
models generally describe the association between an
outcome and a very limited set of potential predictors
only. By adding a broader range of predictors from large
longitudinal databases to build and validate models, per-
haps the biological complexity and heterogeneity can be
better reflected in the resulting outcome predictions.
The use of biomarkers might lead to higher accuracy
than the more general predictors such as age and to-
bacco use.
In the last decennia, the concept of personalized medi-
cine has taken a more central position in metastasized
cancer care. Therefore, future DSS should take into ac-
count specific biological markers and genes, such as
EGFR and ALK. The complexity of gene mutations,
translocations and rearrangements can explain why
some treatments are effective, while others induce little
response in patients. Some systematic reviews have sum-
marized the currently known and relevant NSCLC gen-
etic markers (e.g., EGFR, EML4/ALK mutations), and
other markers for which there is insufficient evidence
for use in clinical decision-making (e.g., K-RAS,
ERCC1, BRCA, Beta tubulin III, RRM1, TP-53 muta-
tions) [70–72]. Genetic markers will become increas-
ingly important in the future in order to distinguish
between responders and non-responders. The same is
true for immunotherapeutic approaches, as for ex-
ample, the NCCN guidelines recommend immune
checkpoint inhibitors for incurable NSCLC patients,
based on performance status and treatment responses
[73]. These guidelines give some insights and flow
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diagrams about the application of two new immuno-
therapeutic agents, nivolumab and pembrolizumab
that target the programmed cell death protein 1 (PD-
1) pathway. However, important insights are still lack-
ing to determine for which patients immunological
treatments are (most) effective, especially considering
that the targeted treatments are costly and some in-
duce severe side effects.
The current systematic review aimed to shed light
on which tools are available, and which gaps remain
to be filled in future research. In general, the available
DSS are of limited value to daily clinical practice be-
cause they used relatively old clinical data (before
2000), focused more on advantages than disadvantages
of merely one or two treatment options, and still lack
available user friendly applications. By collaborating
with national databases, a continuous updating pro-
cedure could be incorporated as well. Recently some
research groups have made new web-based prediction
tools that shed light on both the advantages and dis-
advantages of treatments. One example is the Predict
Cancer website [74], where an application is pre-
sented including DSS for lung, rectum, head and neck
cancer and brain metastases. This application aims to
support oncologists with the estimation of expected
survival rates, side effects of treatments, cost-
effectiveness of a treatment plan, and other important
parameters. As another example, the ASCO, ESMO,
NCCN and Institute for Clinical and Economic Re-
view (ICER) have presented frameworks, in which not
only benefits but also the cost-effectiveness and tox-
icity of several anti-cancer drugs were quantified [75, 76].
Furthermore, Warner et al. have created a novel and
promising rapid learning system for various cancer types
(including lung cancer) that automatically calculates and
displays mutation-specific survival rates from electronic
health record data (69). These approaches could be useful
for future DSS too.
Strengths of the current systematic review are the ex-
tensive literature search performed both in online data-
bases and with reference tracking. We have chosen a
specific population in which decision support can be of
great value because of the short survival time, rapid
treatment-related developments, and complex decisions
about when it still is in the patients’ best interest to pro-
vide invasive treatment, or when the transition needs to
be made to provide only symptom relief. Nevertheless,
some limitations have to be taken into account as well.
Terminology to describe DSS varies greatly throughout
the field, and this could have hampered the ability to
find all existing DSS even with an extensive search strat-
egy. Also, we have not used the complete CHARMS
checklist [15] to assess methodological quality of the in-
cluded DSS, as many items were not reported. Instead
we created an abbreviated list of items that covers the
main aspects of model performance (shown in Table 4).
In the current study, 39 DSS have been identified for
incurable metastatic NSCLC patients. Previously, Mahar
et al. have performed a systematic literature search, and
found 32 tools both for small cell lung cancer (N = 7)
and NSCLC (N = 25) [7]. Of the tools developed for
NSCLC patients, there was one tool for all tumor stages,
eight tools for stages I-III, and 16 for advanced/incurable
disease [7]. Mahar et al. found 16 tools for our target
population, of which three were excluded in our current
search: two were based on older clinical data (before
2000), and one only reported hazard ratios and no for-
mulas for individual probabilities. Furthermore, three of
their included tools were published together in one
paper, and were summarized as one tool in our current
study [77]. To conclude, our systematic literature search
identified 28 additional studies, and added extensive
information about the studies that have externally vali-
dated these DSS, the user friendliness and the applica-
tion methods of the tool in clinical practice.
Conclusions
Our study adds to the current knowledge in the field of
DSS in incurable NSCLC, as conclusions are drawn
about the extent and quality of validation (i.e., Reilly
levels of validation), extent of calibration (i.e., Van
Calster levels of calibration) and user friendliness (i.e.,
routine collection, ease of use, online tools). In
addition, an overview is given of the used predictors,
grouped into domains. Not only does our review in-
creases knowledge of existing DSS, but we also indi-
cate areas for improvement. Overall, we can conclude
that multiple DSS have been developed for incurable
patients with (initial or recurrent) metastatic NSCLC
(stages IIIB and IV), but most of them have used
relatively old clinical data, focused on benefits rather
than harms in terms of toxicity and risks, did not
compare various treatment options, control treatments
(conservative treatment, best supportive care, usual care)
were often poorly or not described, have not been (exter-
nally) validated or still lack available user friendly applica-
tions (i.e., scoring tables, online calculators, mobile
applications). Also, various predictors in the domains of
serum markers, tumor and treatment characteristics have
been included, but apart from EGFR in one DSS, bio-
logical markers for targeted and immunotherapies are still
lacking. Other methods might be available for future DSS
designs in order to incorporate all relevant individual
characteristics efficiently, while taking into account the
needs of oncologists in their daily practice. Preferably, fu-
ture DSS provide oncologists an efficient method to stay
up-to-date with the rapid innovations in lung cancer care.
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